Albert Bourla, CEO of Pfizer, Charlie Scharf, Wells Fargo & Firm CEO and Kathy Warden, Northrop Grumman Chair & CEO communicate through the Put money into America Discussion board on Oct. 15, 2025.
Aaron Clamage | CNBC
Wells Fargo CEO Charlie Scharf and Pfizer CEO Albert Bourla sounded the alarm Wednesday over the potential for the the U.S. to lose its aggressive edge to China, however mentioned synthetic intelligence might assist America keep its lead.
Talking at CNBC’s inaugural Put money into America Discussion board in Washington, D.C., the 2 executives mentioned that whereas the U.S. nonetheless leads in lots of sectors, inconsistent coverage and underinvestment is ceding floor to China. AI, they mentioned, poses each dangers and advantages for the U.S. economic system.
Scharf mentioned AI will doubtless cut back the dimensions of workforces — however will increase productiveness.
“We are going to doubtless have much less folks, completely,” Scharf mentioned. “Once we have a look at the instruments that we have carried out simply for those that are coding, you see 20%, 30%, 40% enchancment in coders. We’ve not diminished our head depend by 20%, 30% or 40%. We’re truly doing greater than we in any other case would have been in a position to do.”
Wells Fargo massive financial institution friends like JPMorgan and Goldman Sachs are already hiring fewer folks due to AI developments.
Scharf additionally mentioned the monetary sector is poised for main regulatory modifications regardless of an ongoing political stalemate in Washington.
“We finally do anticipate important modifications in capital necessities, liquidity necessities,” he mentioned. “We do anticipate to see modifications which can enable folks within the business, not simply massive banks and medium-sized banks, however smaller banks as effectively, to do extra in these [local] communities.”
Bourla, in the meantime, expressed concern about China’s rising energy in biotechnology and prescription drugs, pointing to a surge in analysis and improvement spending, regulatory reforms and a nationwide technique targeted on life sciences.
“They [China] filed extra patents this 12 months than the U.S.,” Bourla mentioned. “That is by no means occurred in historical past. 5 years in the past, the break up was 90%-10%. … The hole is closing, however they most likely will turn out to be [better than us] until we get our act collectively.”
Bourla urged the U.S. to shift focus from attempting to sluggish China’s progress towards bettering its personal productiveness and innovation.
“We spend extra time attempting to consider tips on how to decelerate China slightly than assume how we are able to turn out to be higher than them,” Bourla mentioned. “We have to have regulatory modifications right here. We have to have stability. Tariffs and pricing was not serving to.”
Pfizer not too long ago agreed to a drug pricing deal with the Trump administration as a part of a broader effort to take away long-standing uncertainties round pricing, Medicaid reimbursements and distribution. As a part of the settlement, Pfizer secured a three-year exemption from pharmaceutical-specific tariffs, contingent on further investments in U.S. manufacturing.
“Tariffs and the uncertainty of drastic correction of U.S. pricing — with this deal, we’re eradicating each uncertainties,” Bourla mentioned Wednesday.
He additionally referred to as synthetic intelligence the subsequent frontier for medication, predicting that AI will revolutionize drug discovery by dramatically accelerating timelines for locating remedies for ailments like Alzheimer’s and most cancers.
“We tried for years to search out cures … AI will make it occur,” Bourla mentioned.
